Biogen and Denali Therapeutics will discontinue development of their Parkinson’s disease drug BIIB122 in idiopathic (non-genetic) Parkinson’s disease after a mid‑stage trial failed to slow disease progression. The companies plan to keep studying the drug in patients with a specific genetic mutation linked to Parkinson’s. Sources: Closely watched experimental Parkinson's drug fails key clinical trial Parkinson's drug development halted after midstage trial failure Biogen, Denali begin late-stage testing of Parkinson's drug Biogen cuts PhIII Parkinson's program over 'long timeline' Biogen axes Denali-partnered Parkinson's drug after phase 2 flop Denali Therapeutics Presents Positive Results from Phase 1 and ... Biogen and Denali Therapeutics Provide Update on Phase ... Biogen, Denali pull plug on Parkinson’s program after mid-stage flop Biogen, Denali scrap Parkinson’s drug after failure in mid-to-late stage study Biogen, Denali scrap Par...
- Get link
- X
- Other Apps